I agree @achoud72 fantastic camaraderie, friendship, scholarship! Looking forward to Amsterdam Dec 2-5, 2026! @mirrorsmed @OncoAlert @DrFelixGuerrero @DanieleRaggi83 @Silke_Gillessen @Achard_Verane @bkonety @bm_deruiter @daandm @b_szabados @UroMoschini @LAUrology_NL @mdesantis234

Important work by colleagues @fredhutch led by brilliant Pete Nelson, Bose et al. Deep molecular assessment of LNCaP model: major lessons learned about tumor heterogeneity & prostate Ca treatment resistance; caution on reproduction of results! @OncoAlert https://t.co/kZvN6SFxm2

Primary vs Metastasis: Genomic Differences In the analysis of 5,692 matched primary–metastatic samples from 2,846 patients in the AACR Project GENIE database: 🔹️Metastatic tumors show a modest increase in mutation burden 🔹️FGA is higher → reflecting metastatic genomic

In 2000, the S&P 500 had an elevated trailing P/E of 26, well above its long-term avg. of 14. For the next 11 years, the S&P 500 delivered zero returns! The current S&P 500 trailing P/E is 30 – even higher than 2000. History rhymes. For standardized performance visit our website.

This was a really useful and DETAILED review in @NatureRevCancer on the impact of concomitant medications on treatment outcomes in patients with cancer receiving immune checkpoint inhibitors (everything from antibiotics to analgesics to supplements) https://t.co/OjIY4XdQKM

Personalized ctDNA testing for MRD is transforming adjuvant therapy decisions in muscle-invasive bladder cancer. Petros Grivas covers perioperative insights and key trial data in this 30-min webinar. Watch now: https://t.co/3pTTJrClP8... This content was funded by Natera.

💫🌟IMvigor011 (NEJM 2025) ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer @tompowles1 @cdanicas @AndreaNecchi @DrYukselUrun @dralvaropinto @OncoBellmunt 🔍 Phase III evaluating ctDNA-guided adjuvant immunotherapy after cystectomy. 🧪 Only ctDNA-positive

Another delay on crypto rules and all eyes are on @SenLummis. Is this about policy… or a generational gap in understanding tech? https://t.co/easJqaldUa

Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: Meta-Analysis https://t.co/K1KnuMLrZg Meta-analysis of over 10,000 patients from 13 randomized trials found that the survival benefit of androgen deprivation therapy

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:

This is an alert for physicians and patients!

🔬 Who Should Get Screened for Pancreatic Cancer? Insights from #ESMOGI25 🔎 📌 High-Risk Germline Mutations 🧬 STK11 (Peutz-Jeghers): RR ~132 | Lifetime risk: 11–36% 🧬 PRSS1 (Hereditary Pancreatitis): RR 53–87 | Risk up to 55% by age 70 🧬 CDKN2A (FAMMM): RR 20–40 | Risk 17–25%

"Just-right timing" for fungicide applications can backfire. Agronomist Tim Dahl shares tips for getting the most out of your fungicide in 2026. 🎬

REVELUTION: Coronary Artery Plaque Progression After ADT in Men w/ #ProstateCancer - RCT Comparing Relugolix vs Leuprolide @sagarapatel @urotoday #SUO25 🌞n=28 ADT alone; n=31 RT + leuprolide; n=31 RT + relugolix 🌞BL and 12 mo coronary CT 🌞vs no ADT: Relugolix -- no

Fantastic Global Forum GU Oncology in Lisbon with stellar colleagues, interactive discussions, clinical cases!Next version in Amsterdam Dec 2-5, 2026! @mirrorsmed @OncoAlert @achoud72 @Achard_Verane @LucVanRuysevelt @DanieleRaggi83 @Silke_Gillessen @AOmlin @LAUrology_NL @bkonety

Great discussion with Emeritus Prof. Peter Whelan who led multiple landmark EORTC trials, & my colleague Kirsty B @Bartscancer, specialist in #Oncogeriatrics. We explored the crucial role of comorbidities in PCa treatment. https://t.co/eHuE6ScQfe @urotoday @Uroweb @VJOncology

The @FIFAWorldCup 2026 is on! ⚽️⚽️⚽️⚽️⚽️⚽️⚽️⚽️⚽️⚽️⚽️⚽️⚽️⚽️⚽️

Episode 4 of EBONY x Nationwide: Amplified Rising Visionaries features NFL linebacker Zaire Franklin, founder of Shelice’s Angels, on instant connections, balance, and building impact on & off the field.

✨ New evidence in high-risk prostate cancer staging! ✨ A large multi-institutional study from @Uroweb Young Academic Prostate Cancer group shows that patients staged with PSMA-PET before surgery experience better short-term oncologic outcomes than those staged with

Thanks for sharing @PatrickHwuMD

Thanks for sharing @VivekSubbiah

While discussing ctDNA in bladder Ca #SimposioSOGUG25 more data from IM011 becomes available. Negative patients are at low risk while +ves benefit from atezo. These data further support using ctDNA rather than other approaches to select patients for adjuvant IO in UC #SUO2025

You’ve Chased. Reflected. Revealed. Now it’s time for Lasting Glory. No more hiding behind successes or failures. No more chasing short-lived wins. When your hope is in God’s glory, you serve others, live out your faith and share the Gospel – not just when it’s easy, but always.

What’s the future of muscle invasive bladder cancer #SimposioSOGUG25 Pathological CR rates of 57% for EVP points towards cystectomy being delayed until maximum EVP effectiveness. Also fewer patients will have cystectomy. Studies are needed to ensure this approach is safe.

Sadly, we’ve already arrived at the final session of #PROSCA25: “Looking Ahead: PCa Management in 2026.” A multidisciplinary exploration of the future of prostate cancer care featuring perspectives from a urologist (@roodvdb), a radiation oncologist (@ZilliThomas), a medical